Lipocine (NASDAQ:LPCN) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Lipocine (NASDAQ:LPCN) in a research report sent to investors on Sunday morning. The brokerage issued a buy rating on the specialty pharmaceutical company’s stock.

Lipocine Stock Up 0.7 %

LPCN opened at $4.15 on Friday. The stock’s 50 day moving average price is $4.67 and its 200-day moving average price is $5.34. Lipocine has a one year low of $3.30 and a one year high of $10.48.

Lipocine (NASDAQ:LPCN) last released its quarterly earnings data on Thursday, August 10th. The specialty pharmaceutical company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.04). Equities analysts forecast that Lipocine will post -2.7 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of LPCN. Millennium Management LLC purchased a new position in Lipocine during the 2nd quarter worth $160,000. Renaissance Technologies LLC increased its holdings in Lipocine by 146.2% during the 3rd quarter. Renaissance Technologies LLC now owns 199,400 shares of the specialty pharmaceutical company’s stock worth $90,000 after purchasing an additional 118,394 shares during the period. Goldman Sachs Group Inc. increased its holdings in Lipocine by 524.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 88,615 shares of the specialty pharmaceutical company’s stock worth $121,000 after purchasing an additional 74,428 shares during the period. Wealthspan Partners LLC purchased a new position in Lipocine during the 4th quarter worth $29,000. Finally, EP Wealth Advisors LLC bought a new stake in Lipocine during the 1st quarter valued at $13,395,000. 8.99% of the stock is currently owned by hedge funds and other institutional investors.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.